【中国生物制药(01177.HK)拟44.8亿元向谢承润收购正大天晴5%股权 完成后间接持股增至65%】智通财经APP讯,中国生物制药(01177.HK)发布公告,公司(透过买方Chia Tai Pharmaceutical (Lianyungang)
Company Limited正大医药(连云港)有限公司)拟通过收购目标公司Sino Harmony Ventures
Limited雍华创投有限公司的股权,收购正大天晴5%股权。于2026年9月11日,买方(公司直接全资附属公司)与卖方(公司执行董事及主要股东谢承润先生)就买卖目标股权订立买卖协议,据此,买方有条件同意收购,而卖方有条件同意出售目标股权(相当于目标公司全部已发行股份的100%),代价为人民币44.8亿元,相当于约19倍LTM
PE收购正大天晴5%股权。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.